Tyrosine News and Research RSS Feed - Tyrosine News and Research

Chemical compound eCF506 may be highly effective at blocking growth of breast cancer cells

Chemical compound eCF506 may be highly effective at blocking growth of breast cancer cells

A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests. [More]
Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study. [More]
EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators. [More]
CML treatment-free remission criteria outlined

CML treatment-free remission criteria outlined

Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy. [More]
Novel therapeutic approach to treat leukaemia patients

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms. [More]
Study shows inhibition of SHP-2 enzyme can diminish lupus symptoms

Study shows inhibition of SHP-2 enzyme can diminish lupus symptoms

Researchers at Beth Israel Deaconess Medical Center have identified an enzyme that is significantly elevated in mouse models of systemic lupus erythematosus and in blood samples of patients with lupus. [More]
New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

Obstetricians and midwives are today welcoming the publication of new NICE guidance recommending the use of a new test from Roche Diagnostics that can rule-out the development of the life threatening condition, pre-eclampsia, within one week in pregnant women. [More]
Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics. [More]
Microtubules affect mechanics of beating heart, study finds

Microtubules affect mechanics of beating heart, study finds

On top of the meaning and mystery that humans heap on the heart, it is first and foremost, a muscle. And one that beats about once a second for a person's entire life, with no rest. Given its vital importance, it's ironic researchers have only recently made direct observations of its subcellular parts in motion. [More]
BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers. [More]
Bosutinib shows 'low' vascular, cardiac event risk profile

Bosutinib shows 'low' vascular, cardiac event risk profile

Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia. [More]

Frontline nilotinib supported for newly diagnosed CP-CML

Long-term results from the ENESTnd trial indicate a favourable risk-benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase-chronic myeloid leukaemia diagnosis. [More]

Pre-TKI cytokine profiling predicts CP-CML outcome

Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase-chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests. [More]
Additional chromosomal abnormalities prognostic for CML

Additional chromosomal abnormalities prognostic for CML

Additional chromosomal abnormalities can be used to create two prognostic groups of patients with chronic myeloid leukaemia, suggests research published in Blood. [More]
Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies. [More]
M10 peptide could help protect systemic sclerosis patients against fibrotic damage

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication. [More]
Metabolic pathway activates cell signaling protein to promote breast cancer metastasis

Metabolic pathway activates cell signaling protein to promote breast cancer metastasis

A metabolic pathway that is up-regulated in certain breast cancers promotes the disease's progression by activating a cell signaling protein called Arf6, according to a paper published in the Journal of Cell Biology. [More]
Versatile automated microplate sample screening applications: an interview with Tobias Pusterla

Versatile automated microplate sample screening applications: an interview with Tobias Pusterla

Microplate readers are divided into single-mode and multi-mode readers. A single mode reader is mainly a reader dedicated to the detection of absorbance, luminescence or fluorescence. [More]
Advertisement
Advertisement